NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $3.90 +0.14 (+3.72%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Galectin Therapeutics Stock (NASDAQ:GALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Galectin Therapeutics alerts:Sign Up Key Stats Today's Range$3.75▼$3.9450-Day Range$2.97▼$4.6152-Week Range$2.03▼$7.13Volume220,095 shsAverage Volume294,776 shsMarket Capitalization$256.85 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune-system regulation. The company’s research is aimed at addressing serious diseases for which treatment options remain limited. Its lead product candidate is belapectin, an investigational galectin-3 inhibitor designed to reduce fibrotic activity and potentially improve liver-related complications. Galectin Therapeutics has primarily evaluated belapectin in patients with metabolic dysfunction-associated steatohepatotic cirrhosis, formerly referred to as nonalcoholic steatohepatitis cirrhosis, including complications such as portal hypertension and esophageal varices. Galectin Therapeutics conducts its development activities through clinical research and collaborations in the United States and other relevant markets. As an investigational-stage company, its products remain subject to clinical testing and regulatory review and are not broadly approved as commercial treatments. The company is headquartered in Norcross, Georgia.AI Generated. May Contain Errors. Read More Galectin Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreGALT MarketRank™: Galectin Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 684th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGalectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialGalectin Therapeutics has a consensus price target of $11.00, representing about 182.1% upside from its current price of $3.90.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Galectin Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Galectin Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.91% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 25.16, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 2.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News SentimentN/A News SentimentGalectin Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Galectin Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders52.60% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GALT Stock News HeadlinesGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 2 at 1:00 AM | Behind the Markets (Ad)Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. UihleinAugust 4, 2026 | quiverquant.comQGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance SheetAugust 4, 2026 | globenewswire.comGalectin Therapeutics Insider Trading Activity | NASDAQ:GALT | BenzingaJuly 14, 2026 | benzinga.comGalectin Therapeutics Corporate Event Calendar | NASDAQ:GALTJuly 12, 2026 | benzinga.comGalectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 UpsideJune 24, 2026 | seekingalpha.comSee More Headlines GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $4.16 on January 1st, 2026. Since then, GALT shares have decreased by 6.3% and is now trading at $3.90. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.05. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/14/2026Today10/02/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GALT's financial health is in the Green zone, according to TradeSmith. GALT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GALT CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year Founded2001Price Target and Rating Average Price Target for Galectin Therapeutics$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+182.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.84 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-176.83% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.99) per share Price / Book-1.96Miscellaneous Outstanding Shares65,860,000Free Float31,216,000Market Cap$256.85 million OptionableOptionable Beta0.38 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GALT) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
